• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Oncocyte Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    7/2/25 5:01:52 PM ET
    $OCX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $OCX alert in real time by email
    false 0001642380 0001642380 2025-06-27 2025-06-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    Current Report

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): June 27, 2025

     

    Insight Molecular Diagnostics Inc.

    (Exact name of Registrant as specified in its charter)

     

    California   1-37648   27-1041563
    (State or other jurisdiction
    of incorporation)
      (Commission
    File No.)
      (IRS Employer
    Identification No.)

     

    2 International Plaza Dr., Suite 510

    Nashville, Tennessee 37217

    (Address of principal executive offices) (Zip code)

     

    (949) 409-7600

    Registrant’s telephone number, including area code

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities Registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common stock, no par value   IMDX   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 5.07. Submission of Matters to a Vote of Security Holders.

     

    General

     

    On June 27, 2025, Insight Molecular Diagnostics Inc. (the “Company”) held its 2025 Annual Meeting of Shareholders (the “Annual Meeting”) virtually via live webcast at https://web.lumiconnect.com/259974801. Present at the Annual Meeting virtually or by proxy were holders of 21,008,960 shares of common stock of the Company, which represented 73.46% of the voting power of all shares of common stock of the Company as of May 12, 2025, the record date for the Annual Meeting.

     

    Proposals

     

    The shareholders of the Company voted on the following proposals at the Annual Meeting, as more fully described in the definitive proxy statement on Schedule 14A relating to the Annual Meeting, which was originally filed with the Securities and Exchange Commission on May 14, 2025 (the “Proxy Statement”):

     

    1.To elect the following four (4) director nominees, each to serve until the 2026 annual meeting of shareholders and until his or her successor has been elected and qualified, or until his or her earlier death, resignation, or removal: Joshua Riggs, Andrew Arno, Andrew J. Last and Louis E. Silverman;

     

    2.To ratify the appointment of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for the year ending December 31, 2025

     

    3.To approve, on a non-binding advisory basis, the Company’s named executive officer compensation for the year ended December 31, 2024; and

     

    4.To approve an amendment to the Company’s Amended and Restated 2018 Equity Incentive Plan to increase the total number of shares of the Company’s common stock authorized for issuance under such plan by 1,500,000, to a total of 3,800,000 shares.

     

    Voting Results

     

    The final voting results for each of these proposals at the Annual Meeting are detailed below.

     

    1. Election of Directors

     

          Shares Voted 
    Director Nominee  For  Against  Abstained  Broker Non-Votes 
    Joshua Riggs   18,094,181   6,225   3,890   2,904,664 
    Andrew Arno   18,033,599   66,567   4,130   2,904,664 
    Andrew J. Last   18,041,724   58,642   3,930   2,904,664 
    Louis E. Silverman   18,035,578   64,816   3,902   2,904,664 
                      

     

    Based on the votes set forth above, each director nominee was duly elected to serve until the 2026 annual meeting of shareholders and until his or her successor has been elected and qualified, or until his or her earlier death, resignation, or removal.

     

    2. Ratification of Appointment of Accounting Firm

     

    Shares Voted
    For  Against  Abstained  Broker Non-Votes
    20,986,994  4,951  17,015  0

     

    Based on the votes set forth above, the shareholders ratified the appointment of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for the year ending December 31, 2025.

     

     

     

     

    3. Say On Pay Proposal

     

    Shares Voted
    For  Against  Abstained  Broker Non-Votes
    18,063,639  28,647  12,010  2,904,664

     

    Based on the votes set forth above, the shareholders approved, on a non-binding advisory basis, the Company’s named executive officer compensation for the year ended December 31, 2024.

     

    4. Approval of Amendment to Amended and Restated Incentive Plan

     

    Shares Voted
    For  Against  Abstained  Broker Non-Votes
    17,958,519  140,508  5,269  2,904,664

     

    Based on the votes set forth above, the shareholders approved the amendment to the Company’s Amended and Restated 2018 Equity Incentive Plan to increase the total number of shares of the Company’s common stock authorized for issuance under such plan by 1,500,000, to a total of 3,800,000 shares.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      INSIGHT MOLECULAR DIAGNOSTICS INC.
         
    Date: July 2, 2025 By: /s/ Peter Hong
      Name: Peter Hong
      Title: Vice President, General Counsel

     

     

     

    Get the next $OCX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $OCX

    DatePrice TargetRatingAnalyst
    3/28/2025$5.00Buy
    Lake Street
    5/24/2022Overweight → Equal-Weight
    Stephens
    3/14/2022Overweight → Sector Weight
    KeyBanc Capital Markets
    3/11/2022$11.00 → $6.00Buy
    Lake Street
    3/11/2022$5.00 → $4.00Buy
    Needham
    1/7/2022$3.10Overweight
    Stephens & Co.
    1/6/2022$3.10Overweight
    Piper Sandler
    12/16/2021$7.00 → $5.00Buy
    Needham
    More analyst ratings

    $OCX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville

      New name aligns with mission to deliver precision biomarker-based testing for both transplant and oncology careiMDx sponsoring GraftAssureIQ™ research-use-only kits at transplant labs globallyExhibiting at European Society of Organ Transplantation (ESOT) conference in London, June 29 – July 2, 2025 NASHVILLE, Tenn., June 17, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. ("iMDx" or the "Company"), (NASDAQ:IMDX), formerly known as Oncocyte Corporation (NASDAQ:OCX), has announced its renaming and the relocation of its principal executive office from Irvine, California, to Nashville, Tennessee. The Company's common stock, listed on the Nasdaq Capital Market, will begin trading

      6/17/25 7:00:00 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Medicare Boosts Reimbursement for Oncocyte's Flagship Technology

      New price of $2,753 for the GraftAssureCore™ assay increases total addressable market size and margin opportunityBrings pricing in line with existing competitive technologyExpands market appeal for prospective FDA-cleared kitted product at transplant centers IRVINE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (NASDAQ:OCX), a diagnostics technology company, today provided a positive update on pricing for its next-generation lab-developed test (LDT), GraftAssureCore. The new reimbursement rate strengthens the company's position in the growing transplant rejection testing market and suggests potential upside to its estimated $1 billion total addressable market. The Centers for

      5/19/25 4:05:00 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Oncocyte Reports Q1 2025 Results and Business Progress

      Q1 2025 pharma services revenue of $2.1 million, at 62% gross marginThree of the top 10 U.S. transplant centers expected to participate in clinical trialTen globally leading transplant hospitals are now using our GraftAssure research-use-only kitsTo reflect our larger market opportunity, we plan to rename the company in Q2 IRVINE, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a diagnostics technology company, today published the following letter to shareholders in conjunction with its first quarter results: Fellow Shareholders,We're off to a fast and intensely focused start in 2025. Just two months ago, we shared our strategic outlook — and sin

      5/12/25 4:05:00 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $OCX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on OncoCyte with a new price target

      Lake Street initiated coverage of OncoCyte with a rating of Buy and set a new price target of $5.00

      3/28/25 8:35:58 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • OncoCyte downgraded by Stephens

      Stephens downgraded OncoCyte from Overweight to Equal-Weight

      5/24/22 8:51:33 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • OncoCyte downgraded by KeyBanc Capital Markets

      KeyBanc Capital Markets downgraded OncoCyte from Overweight to Sector Weight

      3/14/22 7:21:22 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $OCX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Arno Andrew was granted 55,000 shares, increasing direct ownership by 67% to 136,554 units (SEC Form 4)

      4 - Insight Molecular Diagnostics Inc. (0001642380) (Issuer)

      7/3/25 4:05:25 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Silverman Lou was granted 35,000 shares, increasing direct ownership by 2,238% to 36,564 units (SEC Form 4)

      4 - Insight Molecular Diagnostics Inc. (0001642380) (Issuer)

      7/3/25 4:05:34 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Last Andrew J. was granted 35,000 shares, increasing direct ownership by 776% to 39,509 units (SEC Form 4)

      4 - Insight Molecular Diagnostics Inc. (0001642380) (Issuer)

      7/3/25 4:05:22 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $OCX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer James Andrea S. bought $200,000 worth of shares (97,561 units at $2.05), increasing direct ownership by 182% to 151,231 units (SEC Form 4)

      4 - Oncocyte Corp (0001642380) (Issuer)

      2/11/25 7:00:32 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Large owner Smith Patrick W bought $2,209,080 worth of shares (1,077,600 units at $2.05) and acquired $790,919 worth of shares (385,814 units at $2.05) (SEC Form 4)

      4 - Oncocyte Corp (0001642380) (Issuer)

      2/11/25 5:00:15 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Large owner Broadwood Partners, L.P. bought $10,589,675 worth of shares (5,165,695 units at $2.05) (SEC Form 4)

      4 - Oncocyte Corp (0001642380) (Issuer)

      2/10/25 8:43:04 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $OCX
    SEC Filings

    See more
    • Oncocyte Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Insight Molecular Diagnostics Inc. (0001642380) (Filer)

      7/2/25 5:01:52 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Oncocyte Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Oncocyte Corp (0001642380) (Filer)

      6/17/25 7:33:46 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form DEFA14A filed by Oncocyte Corporation

      DEFA14A - Oncocyte Corp (0001642380) (Filer)

      5/14/25 5:08:11 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $OCX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Oncocyte Corporation

      SC 13G/A - Oncocyte Corp (0001642380) (Subject)

      12/9/24 5:30:06 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G filed by Oncocyte Corporation

      SC 13G - Oncocyte Corp (0001642380) (Subject)

      11/14/24 1:26:16 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Oncocyte Corporation

      SC 13G/A - Oncocyte Corp (0001642380) (Subject)

      10/24/24 12:13:28 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $OCX
    Financials

    Live finance-specific insights

    See more
    • Oncocyte to Release First Quarter 2025 Results on May 12, 2025

      IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (NASDAQ:OCX), a leading diagnostics technology company, today announced that it will report first quarter 2025 financial results after the market closes on Monday, May 12, 2025. Oncocyte will host a live Zoom webinar to discuss the company's financial results at 2:00 p.m. PT that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: Oncocyte Q1 2025 Earnings Webinar. An archived replay will be available after the call concludes on Oncocyte's investor relations website at https://investors.oncocyte.com. About Oncocyte Oncocyte is a pioneering di

      5/7/25 4:10:00 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Oncocyte Provides Positive Update on Clinical Trial Progress

      Central Institutional Review Board approved, final preparatory steps underway at first transplant centersThree of the top 10 U.S. transplant centers expected to participate in trialNearly 10% of annual U.S. transplant volume represented in trial site interestPreparing for final Q-sub FDA meeting ahead of clinical validation IRVINE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (NASDAQ:OCX), a leading diagnostics technology company, today provided a positive update on its substantial progress toward initiating its clinical trial, which is a major step required to obtain regulatory authorization to deliver an organ transplant rejection monitoring test kit to the market. Oncoc

      4/30/25 8:30:00 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • STAAR Surgical Announces Changes to Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

      4/24/25 5:00:00 PM ET
      $AZN
      $CRVL
      $LLY
      $MDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Insurers
      Finance

    $OCX
    Leadership Updates

    Live Leadership Updates

    See more
    • Veradigm Announces Board Expansion and Changes

      Appoints Vinit Asar and Louis Silverman to its Board of Directors Agrees to Add Two Additional Directors Veradigm® (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today it has entered into a Cooperation Agreement (the "Agreement") with Kent Lake PR LLC ("Kent Lake"). The Agreement aligns with the Board's request for input from shareholders regarding board composition on January 30, 2025, and a desire to conduct an orderly refreshment of the Board following the conclusion of the exploration of strategic alternatives. As part of the Agreement, the Board has appointed two new independent directors, Vinit Asar and Louis Silve

      2/20/25 4:02:00 PM ET
      $MDRX
      $OCX
      $ZIMV
      EDP Services
      Technology
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer

      Dr. Billings is a renowned diagnostics specialist with a history of commercializing novel assays in precision medicineWill provide key regulatory and reimbursement supportWill assist business development efforts and strategic partnerships IRVINE, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a diagnostics technology company, announces the appointment of Dr. Paul Billings as the company's Consulting Chief Medical Officer. In this part-time role, he will support a range of strategic and clinical goals for Oncocyte. Dr. Billings is a recognized pioneer in genomics and precision medicine with over 40 years of experience spanning academia, government,

      1/8/25 8:30:00 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move

      NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leader within the financial markets and news community, announces the release of an article highlighting the precision diagnostics company, Oncocyte's (NASDAQ:OCX) appointment of leading finance executive, Andrea James, as Chief Financial Officer. This strategic move comes at a pivotal time as Oncocyte prepares for significant commercial and regulatory milestones expected in 2024 and 2025. Under the leadership of CEO Josh Riggs, Oncocyte is poised for a transformative period with its upcoming commercial launches. The company's flagship products, the VitaGraft™ Kidney diagnostic test and its research use only (RUO) GraftAssure

      6/24/24 12:41:19 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care